Four Deaths Prompt FDA Safety Concerns About Novel Schizophrenia Drug

FDA flags four deaths in Newron's schizophrenia drug studies

The FDA identified four deaths among patients treated with Newron Pharmaceuticals' experimental schizophrenia drug evenamide in feedback following the agency's earlier decision to place the trial on hold.